Saturday, December 12, 2020 2:42:17 PM
RVVTF may turn out to be a MONSTER monster stock, way bigger than the Phase III Covid19 drug trial that is why I already bought shares the last 12 weeks.
Reviewing why I had already bought:
It's Bucillamine Rx Drug has a 30 year safety history of use in Japan and So. Korea as a Rheumatoid Arthritis drug, thus has potential for keeping the immune system from killing people that get Covid19 (thus the phase III EUA FDA trial). That is why I bought shares and went long the last 12+ weeks
But, from what I just read, it looks like (the theory is sound IMHO) it can also deactivate Corona Viruses, all of them, as well. If the trials show it can disable the ability of corona viruses like Covid19, to invade and infect and take over cells, that it needs to seize control of to replicate, that is going to be game changer huge, as Covid19 and its future descendants are here with us to stay now.
It is in the wild. It is a Virus, it will mutate, because that is what they do.
Vaccines may only be a 6 month fix, before annual or Bi-annual booster shots are needed.
Bucillamine would not be a one dose cure. But a take it for days, at the first signs and symptoms or positive test...,drug, world wide.
Moderna Vaccine may work longer, but that verdict is not in. And being the first sRNA vaccine there is no long term safety history yet (It may be the safest vaccine ever, or ???) compared to RVVTF's Bucillamine.
Market cap of RVVTF is under 50 Mil dollars (thus not a bloated way overvalued pig) and for a real Drug firm, that is re-purposing safe, low cost to produce existing drugs, that is crazy cheap.
It is a Canadian reporting Drug firm. Trades on Frankfurt, Canadian and piggy backed on US OTC stock exchanges.
Covid19 early clinical drug trial data on the Bucillamine is due in about 2 weeks. So the current rally may top in 2-3 weeks. $2 to $3 looks realistic and reasonable.
If the paper (link to the pdf copy is attached below), theory and data are proven correct, and if it can in fact disable the ability of Corona/Covid19 Virus to infect cells, $10/share is possible? That would give it a Billion dollar market cap.
Quote from the paper I linked:
Title: Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence
from in vitro SARS-CoV-2 infection studies.
Summary: Thiol-based drugs decrease binding of SARS-CoV-2 spike protein to its receptor and inhibit SARS-CoV-2 cell entry.
NAC-aka N-Acytyl Cysteine (It is a Thiol based supplement...that regenerates Glutathione, and is already part of some MD's battle plans being used to fight Covid19.
Bucillamine is 16 times more active than NAC in the Thiol group activity/ability...
Here is the 22 page paper (I found here 2 days ago, and Finally got to scan-read the first page. I will cut and paste more comments as I read the rest of the paper, when I have time, if what I read adds anything to this story that is note worthy).
I will be buying more shares of RVVTF based on this.
https://cdn.discordapp.com/attachments/462311906129084418/787396887425712238/2020.12.08.415505v1.full.pdf
All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
